Article

Seattle Times on 2021-10-20 16:47

Biogen CEO: ‘Major bottleneck’ still limits Alzheimer’s drug

A new Alzheimer’s drug from Biogen brought in only $300,000 in sales during its first full quarter on the market, continuing a slow debut complicated ...

Related news

Biogen to replace CEO after Alzheimer’s drug flops journalrecord.com
Europe , Wall Street , Massachusetts , Cambridge
Biogen CEO Stepping Down After Struggles With Alzheimer’s Drug Aduhelm Forbes
Cambridge
Biogen cuts the price for its Alzheimer’s drug in half pressherald.com
Massachusetts , Cambridge , Japan
Biogen cuts Alzheimer’s drug price 50% months after approval Seattle Times
New York , Cambridge
An Alzheimer’s Drug Was Supposed to Be a Blockbuster for Biogen. Its Failure Cost the CEO His Job.observer.com
Mount Sinai
Biogen tabs veteran pharma leader Viehbacher as next CEO seattletimes.com
Cambridge , France
Biogen cuts the price tag on its Alzheimer’s drug in half Seattle Times
Massachusetts , Cambridge
Panels find FDA, Biogen rushed Alzheimer’s drug Arkansas Online
Philadelphia , Cambridge
BBiogen Earnings Were Good, but an Alzheimer’s Drug Delay Hits Shares barrons.com
Stock Island , Massachusetts
HBiogen Cuts the Price Tag on its Alzheimer’s Drug in Half hamodia.com
Japan , Cambridge
Biogen CEO scoops up $2.3M Back Bay condo bizjournals.com
Suffolk , Cambridge
Biogen dumps dubious Alzheimer’s drug after profit-killing FDA scandal Ars Technica
Phase 4 , Switzerland , Massachusetts , Cambridge
BBiogen Stock Is Soaring as Hope Returns for Alzheimer’s Drug barrons.com
Wall Street , Stock Island
Biogen applies to market Alzheimer’s disease treatment in the US New York Post
Japan
BBiogen Announces New Trial for Alzheimer’s drug Aduhelm2 min read barrons.com
Biogen Submits Promising Alzheimer’s Drug Aducanumab to FDA for Approval observer.com
Alzheon's CEO says he can beat Biogen with the world’s first Alzheimer’s drug bizjournals.com
Framingham
FFDA approves Biogen Alzheimer’s drug ft.com